

Company Overview

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and allergy, dermatology, and rheumatology.

The leading prescription products are GRAFAPEX and Trecondyv, indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT); IXINITY, for control & prevention of bleeding episodes & for perioperative management of patients with Hemophilia B; Rasuvo and Metoject, unique formulations of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases and Rupall, an innovative allergy medication with a unique mode of action.

Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Feb 11 2026, 5:30 PM EST

Medexus Schedules Third Fiscal Quarter 2026 Conference Call

Feb 3 2026, 5:30 PM EST

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

Nov 20 2025, 7:30 AM EST

Management Team

Ken d'Entremont

Chief Executive Officer and Director

Brendon Buschman

Chief Financial Officer

Ian C Wildgoose Brown

General Counsel

Richard Labelle

Chief Operating Officer

Medexus Pharmaceuticals, Inc.

10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.